title: Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection.
abstract: The kinetics and magnitude of SP receptor expression was determined for bronchoalveolar leukocyte cell subsets from BALB/c mice in the primary immune response to respiratory syncytial virus (RSV) and human parainfluenza virus-3 (PIV3) infection, and in the secondary immune response to RSV and PIV3 challenge. In both the primary and secondary responses to infection, expression of substance P (SP) receptors was markedly increased by infection, especially for T lymphocytes, compared to B220+, CD11b+ and CD14+ cells. CD4+ T lymphocytes predominantly expressed SP receptors in the secondary response. These results suggest that SP receptor expression may be important in the development of primary and secondary immune responses to respiratory virus infections.
authors.affiliation: Division of Viral and Rickettsial Diseases, National Center of Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. rgt3@cdc.gov
authors.forename: Ralph A
authors.initials: RA
authors.lastname: Tripp
authors.forename: Albert
authors.initials: A
authors.lastname: Barskey
authors.forename: Laura
authors.initials: L
authors.lastname: Goss
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Anderson
mesh_terms: D000818:Animals; D000918:Antibody Specificity / Q000276:immunology; D015703:Antigens, CD; D000954:Antigens, Surface / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation / Q000276:immunology; D051917:Leukosialin; D008024:Ligands; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D051379:Mice; D008807:Mice, Inbred BALB C; D010224:Parainfluenza Virus 3, Human / Q000276:immunology* / Q000472:pathogenicity; D011485:Protein Binding / Q000187:drug effects / Q000276:immunology; D018040:Receptors, Neurokinin-1 / Q000187:drug effects / Q000276:immunology*; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology* / Q000503:physiopathology; D012136:Respiratory Syncytial Viruses / Q000276:immunology* / Q000472:pathogenicity; D010253:Respirovirus Infections / Q000276:immunology* / Q000503:physiopathology; D012795:Sialoglycoproteins / Q000276:immunology; D013373:Substance P / Q000276:immunology* / Q000494:pharmacology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D000954:Antigens, Surface; D016207:Cytokines; D051917:Leukosialin; D008024:Ligands; D018040:Receptors, Neurokinin-1; D012795:Sialoglycoproteins; C497863:Spn protein, mouse; D013373:Substance P